55 completed, 10 unknown, 7 not yet recruiting, 7 recruiting. 34 Phase 2, 28 Phase 3, 7 Phase 1, 4 Not applicable, 3 Phase 4.
Follow Non-Squamous Non-Small Cell Lung Cancer: new trials by email Literature Review of Non-Squamous Non-Small Cell Lung Cancer trials Research Report on Non-Squamous Non-Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | AbbVie | 660 | 2027-01-06 | 2026-10-05 |
| SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study SHR-A2009 + bevacizumab, Sacituzumab Tirumotecan - Non-squamous Non-small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 490 | 2026-11-30 | 2026-10-26 |
| A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) BL-B01D1, PD-1/VEGF Bispecific Antibody, Tislelizumab - Non-squamous Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 166 | 2026-11-01 | 2026-10-28 |
| A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure SKB264+SKB118 - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 110 | 2026-10-15 | 2026-10-02 |
| A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC BL-M07D1, Pembrolizumab - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 80 | 2026-02-03 | 2026-03-05 |
| A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC BL-M07D1, Pembrolizumab, Pemetrexed - Non-squamous Non-small Cell Lung Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 440 | 2025-09-29 | 2025-11-17 |
| A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi) - Non-Squamous Non-Small Cell Lung Cancer, c-MET | Phase 2 / Phase 3 | Recruiting | AbbVie | 854 | 2025-08-03 | 2026-10-05 |
| A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer HLX17, US-sourced Keytruda®, EU-sourced Keytruda® - Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 772 | 2025-04-27 | 2025-02-26 |
| Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy JS207, Pemetrexed, Carboplatin or cisplatin - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 78 | 2025-03-30 | 2026-05-18 |
| A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors B1962 - Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC) | Phase 2 | Not yet recruiting | Tasly Biopharmaceuticals Co., Ltd. | 120 | 2024-12-01 | 2024-12-09 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC Rilvegostomig, Pembrolizumab, Carboplatin - Non-squamous Non-small Cell Lung Cancer | Phase 3 | Recruiting | AstraZeneca | 1160 | 2024-11-27 | 2026-10-28 |
| Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) FYB206, Keytruda - Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Terminated | Formycon AG | 25 | 2024-10-03 | 2025-06-26 |
| RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil Non-squamous Non-Small Cell Lung Cancer | Recruiting | AstraZeneca | 250 | 2024-07-25 | 2026-09-23 | |
| A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer HS-20117, Aumolertinib - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Recruiting | Hansoh BioMedical R&D Company | 1080 | 2024-05-28 | 2025-08-01 |
| A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin, Camrelizumab + Pemetrexed + Carboplatin, Adebrelimab + Pemetrexed + Carboplatin - Non-squamous Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Shengdi Pharmaceutical Co., Ltd | 401 | 2024-03-01 | 2024-03-28 |
| Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure Serplulimab, Bevacizumab Biosimilar HLX04, Pemetrexed - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Unknown | Henan Cancer Hospital | 46 | 2023-05-08 | 2024-03-28 |
| Phase III Study of AK112 for NSCLC Patients AK112 Injection, Placebo Injection - Non-Squamous Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | Summit Therapeutics | 420 | 2023-05-04 | 2026-07-28 |
| A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications AMG 794 - Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer | Phase 1 | Terminated | Amgen | 3 | 2023-02-28 | 2025-10-08 |
| Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA Tusamitamab ravtansine - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Terminated | Sanofi | 22 | 2022-06-01 | 2025-08-29 |
| Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed - Non-squamous Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Unknown | Sichuan Cancer Hospital and Research Institute | 20 | 2022-06-01 | 2022-05-27 |
Showing 20 of 91. Sign in to see all of them.
Lung Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasms (2) · Uterine Cervical Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Rectal Neoplasms (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1)
Neoplasms by Site (12) · Neoplasms (11) · Lung Diseases (10) · Respiratory Tract Diseases (10) · Respiratory Tract Neoplasms (10) · Thoracic Neoplasms (10) · Bronchial Neoplasms (6) · Carcinoma, Bronchogenic (6) · Lung Neoplasms (4) · Carcinoma (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3)
Erlotinib Hydrochloride (22) · Bevacizumab (21) · Pemetrexed (21) · Carboplatin (20) · Cisplatin (19) · Paclitaxel (9) · Docetaxel (6) · Gemcitabine (6) · onartuzumab (4) · pembrolizumab (4) · anlotinib (3) · Platinum (2) · imgatuzumab (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine (1)
Hoffmann-La Roche (44) · Genentech, Inc. (6) · AbbVie (3) · Sichuan Baili Pharmaceutical Co., Ltd. (3) · AstraZeneca (2) · Affiliated Hospital of Hebei University (1) · Akeso (1) · Amgen (1) · Bio-Thera Solutions (1) · Bristol-Myers Squibb (1) · Dong Wang (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Formycon AG (1) · Fujian Cancer Hospital (1) · Hansoh BioMedical R&D Company (1)
China (23) · France (23) · Spain (22) · Germany (21) · United States (21) · Italy (20) · United Kingdom (14) · Taiwan (13) · Canada (12) · Netherlands (11) · Australia (10) · Belgium (10) · Poland (10) · South Korea (10) · Argentina (9)
Cesare Gridelli, M.D. (1) · Dingzhi Huang, M.D. (1) · Dong Wang, PH.D (1) · Edward Aten, MD (1) · Francisco Robert, MD (1) · Ina Rhee, M.D., Ph.D. (1) · Ivor Caro, M.D. (1) · Li Zhang, MD (1)
PMID 20150572, PMID 20650686, PMID 20978447, PMID 21245868, PMID 21705281, PMID 22025157, PMID 22967997, PMID 23018280, PMID 23782814, PMID 23835708, PMID 24687921, PMID 26720423, PMID 26828788, PMID 27619516, PMID 27979383, PMID 29438092, PMID 29525239, PMID 29587656, PMID 29801465, PMID 30017645, PMID 30177994, PMID 30603797, PMID 30642441, PMID 31077164, PMID 31542806, PMID 32115349, PMID 32276179, PMID 33067126, PMID 33241650, PMID 33737340, PMID 34226144, PMID 35331641, PMID 35659580, PMID 35727053, PMID 35908558, PMID 36428744, PMID 37004206, PMID 37156249, PMID 37696652, PMID 38820549, PMID 39485534, PMID 41592891, PMID 42307937, PMID 42636833
2008 (5), 2004 (1), 2014 (1), 2015 (1), 2017 (1), 2023 (1), 2025 (1)